E-resources
PDF-
Kuiper, Justine L; Hendriks, Lizza E; van der Wekken, Anthonie J; de Langen, Adrianus J; Bahce, Idris; Thunnissen, Erik; Heideman, Daniëlle A.M; Berk, Yvonne; Buijs, Ed J.M; Speel, Ernst-Jan M; Krouwels, Frans H; Smit, Hans J.M; Groen, Harry J.M; Dingemans, Anne-Marie C; Smit, Egbert F
Lung cancer, 09/2015, Volume: 89, Issue: 3Journal Article
Highlights • This is the largest study reporting on leptomeningeal metastasis (LM) in EGFR -mutated NSCLC-patients. • Median survival of EGFR -mutated NSCLC-patients with LM was 3.1 months. • Survival after LM-diagnosis in EGFR -mutated NSCLC-patients with LM may not be superior compared to existing data on that in EGFR -wild type NSCLC patients. • Six- and 12-month survival rates were 43.8% and 18.8%, respectively.
